Filing Details
- Accession Number:
- 0001437749-14-011098
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-12 17:09:35
- Reporting Period:
- 2014-06-10
- Filing Date:
- 2014-06-12
- Accepted Time:
- 2014-06-12 17:09:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1484478 | Furiex Pharmaceuticals Inc. | FURX | Pharmaceutical Preparations (2834) | 271197863 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1181153 | S Paul Covington | C/O Furiex Pharmaceuticals, Inc., 3900 Paramount Parkway, Suite 150 Morrisville NC 27560 | Senior Vp-Clinical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-06-10 | 2,872 | $104.63 | 25,751 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (to buy) | $9.11 | 2020-06-17 | 45,691 | 45,691 | Direct | |
| Common Stock | Stock Options (to buy) | $15.00 | 2021-05-09 | 26,000 | 26,000 | Direct | |
| Common Stock | Stock Options (to buy) | $13.16 | 2021-10-03 | 37,944 | 37,944 | Direct | |
| Common Stock | Stock Options (to buy) | $17.80 | 2022-02-24 | 10,368 | 10,368 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2020-06-17 | 45,691 | 45,691 | Direct |
| 2021-05-09 | 26,000 | 26,000 | Direct |
| 2021-10-03 | 37,944 | 37,944 | Direct |
| 2022-02-24 | 10,368 | 10,368 | Direct |
Footnotes
- Represents shares sold in connection with the satisfaction of tax liabilities incurred upon the vesting of restricted stock granted June 10, 2013.
- All options became 100% vested on June 11, 2014 in connection with the Agreement and Plan of Merger dated as of April 27, 2014 by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc.
Billionaire Hedge Funds
